

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/088,866
Filing Date	July 2, 2002
First Named Inventor	Michael SCHIRNER et al.
Group Art Unit	1641
Examiner Name	UNASSIGNED
Attorney Docket Number	SCH 1869

## U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

~~SEP 09 2002~~

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date Considered

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/088,866
Filing Date	July 2, 2002
First Named Inventor	Michael SCHIRNER et al.
Group Art Unit	1641
Examiner Name	UNASSIGNED
Attorney Docket Number	SCH 1869

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SSH		International Search Report	
SSH		Neri Dario et al., "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform", Nature Biotechnology, Bd. 15, Nr. 12, 1997, Seiten. 1271-1275, XP002124779	
		<del>Zusammenfassung, Seite 1271, Spalte 2, Absatz 2, Seite 1273, Spalte 1, Absatz 5, Seite 1273, Spalte 2, Absatz 4, Seite 1274, Absatz 1, Seite 1274, Spalte 2, letzter Absatz, Seite 1275, Spalte 1, Absatz 1</del>	
SSH		Viti F. et al., "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis", Cancer Research, (1999 Jan 15) 59 (2) 347-52 XP002124782	
		<del>Zusammenfassung Abbildung 4, Seite 361, Spalte 1, letzter Absatz, Spalte 2, Absatz 1</del>	
SSH		Mariani G. et al., "Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants", Cancer (1997 Dec 15) 80 (12 Suppl) 2378-84 XP000960444	
SSH		Castellani P. et al., "The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis published erratum appears in Int J. Cancer 1995 Jul 4; 62(1):1181", International Journal of Cancer (1994 Dec 1) 59 (5) 612-8, XP000960445	
SSH		Poon et al., "Laser-Induced fluorescence: experimental intraoperative delineation of tumor resection margins", STN Cephus, XX,XX, Bd. 25, Nr. 118, 22 Juni 1992 (1992-06-22), XP002076252 Zusammenfassung	
		<del>Seite 2378, Spalte 2, Absatz 1, Seite 2379, Spalte 1, Absatz 4, Seite 2379, Spalte 2, letzter Absatz, Seite 2380, Spalte 1, Absatz 1, Seite 2381, Spalte 1, letzter Absatz, Seite 2383, Spalte 1, Absatz 1</del>	
		<del>Seite 612, Spalte 2, Absatz 3, Seite 614, Spalte 1, Absatz 3, Spalte 2, Absatz 1, Seite 616, Spalte 1, Absatz 3, Spalte 2, Absatz 2</del>	

Examiner Signature		Date Considered	2/7/05
--------------------	--	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JER:mb

K:\Sch1869\pto-1449 9-6-02.dot

# RECEIVED

SEP 09 2002

TECH CENTER 1600/2900